BioCryst Pharmaceuticals to Report Q4 2025 Financial Results on February 26

Thursday, Feb 5, 2026 7:02 am ET1min read
BCRX--

BioCryst Pharmaceuticals will report its Q4 2025 financial results on February 26, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. BioCryst is a biotechnology firm focused on developing and commercializing medicines for hereditary angioedema and other rare diseases. The company has commercialized ORLADEYO, a once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics.

BioCryst Pharmaceuticals to Report Q4 2025 Financial Results on February 26

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet